BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...
BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...
BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue PR Newswire BERGEN, Norway, May 26, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR...
BerGenBio ASA: Proposed partially underwritten rights issue PR Newswire BERGEN, Norway, April 25, 2023 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES...
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11 mutations, KEAP1m identified as being associated with...
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11 mutations, KEAP1m identified as being associated with...
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations PR Newswire BERGEN, Norway, March 9, 2023 - Global...
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations PR Newswire BERGEN, Norway, March 9, 2023 - Global...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 4600 | 4600 | 4600 | 1788 | 4600 | DE |
4 | 0 | 0 | 4600 | 4600 | 4600 | 1277 | 4600 | DE |
12 | 0 | 0 | 4600 | 4600 | 4600 | 722 | 4600 | DE |
26 | 0 | 0 | 4600 | 4600 | 4600 | 2440 | 4600 | DE |
52 | 0 | 0 | 4600 | 4600 | 4600 | 88442 | 4600 | DE |
156 | 0 | 0 | 4600 | 4600 | 4600 | 76222 | 4600 | DE |
260 | 0 | 0 | 4600 | 4600 | 4600 | 47652 | 4600 | DE |
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관